Biotech Index – European Biotech Companies in the Spotlight

In the European Biotech Index, two stocks were exchanged at the latest adjustment date at the beginning of July. The shares of Cellectis and Oncopeptides were replaced by Formycon and Uniqure. The index comprises the 30 largest listed biotechnology companies from the European Union and the United Kingdom. In the current year, the stock barometer, which also includes the shares of Corona vaccine manufacturer BioNTech, is one of the strongest indices in Europe.

Biotechnology has long been nothing new. For thousands of years, mushrooms have been used to produce foods such as bread, beer, cheese, and wine. According to an analysis by the research company Global Markets Insights (GMI), around $497 billion were generated with biotechnologically developed products in 2020 – a large part of this in the biopharma segment. The experts at GMI expect that the biotech market volume could continue to grow by an average of 9.4 percent per year until 2027. Already today, a large proportion of the top-selling drugs come from the laboratory of a biotech company. Many investors tend to look to the USA for biotech investments. However, there has long been a promising biotechnology sector in Europe.

If you want to find more details about the European Biotech Index and why biotech companies in Europe are now in the spotlight, download for free the Born2Invest mobile app. Our companion app brings you the latest market updates and the most important business headlines so you can stay on top of the market.

Numerous companies now have a market capitalization of over one billion euros and numerous products in the pipeline

Genmab from Denmark, for example, focuses on the development of antibody therapies against cancer. MorphoSys from Germany, together with Johnson & Johnson subsidiary Janssen, has Tremfya, a treatment for psoriasis, on the market. With Gantenerumab for Alzheimer’s disease, Otilimab for arthritis, and MOR202 for cancer, MorphoSys has three other candidates in phase III. Argenx of the Netherlands is conducting research in the field of antibody therapies with a focus on cancer and autoimmune diseases. BioArctic’s partner Eisai reported in late June that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy status to lecanemab. Recently, lecanemab entered Phase III for the treatment of Alzheimer’s disease, and BioArctic’s stock surged following the news. Pharmaceutical giants have long recognized the potential of European biotech companies and are cooperating with groups such as MorphoSys. In addition, biotechnology companies are popular targets for takeovers.

The index certificate reflects the performance of the index. If the index rises, the index certificate also profits. Biotechnology companies are mainly dependent on their research results. If they show success, a certificate rises. If studies produce disappointing results or if the development of a drug has to be discontinued, the share price may collapse.

__

(Featured image by hpgruesen via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FinanzNachrichten.de, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.